CEO Eugene Ciolfi

Eugene Ciolfi

President and CEO

Eugene Ciolfi joined MedPharm as President and CEO in 2018. Specialising in in sterile and non-sterile topical dosage forms, Gene brings with him over 25 years’ senior executive and technical experience in the CDMO and pharmaceutical sectors (including DPT, Bausch and Lomb Pharmaceuticals and Bio-Pharm Inc). During his time at DPT Laboratories he led the transformation of the Lakewood, NJ site into the Center of Excellence for Sterile and Specialty Products, becoming one of the leading CDMO's for sterile liquids, injectables, nasals and semi-solids. In 2016 Gene joined Torrent Pharmaceuticals as the Vice President and Site Head of US Operations.

Dr. Andrew G. Muddle

Co-founder and Ambassador

Andrew Muddle co-founded MedPharm in August 1999. He has spent over 25 years in pharmaceutical drug delivery in roles of increasing seniority. He has focused on ensuring MedPharm’s commercial proposals meet customers’ expectations and oversight of the consistent and impressive growth of the company from its very beginnings. Prior to MedPharm, Andrew was Technical Director (Pharmaceutical Development) at PowderJect Pharmaceuticals plc where he was pivotal in its IPO in 1997.

Prof. Marc Brown PhD CChem FRSC

Chief Scientific Officer and Co-founder

Marc Brown co-founded MedPharm in August 1999. He has been the guiding force behind all of MedPharm’s scientific developments and intellectual property. He has been Professor of Pharmaceutics in the School of Pharmacy, University of Hertfordshire since 2006 and has visiting/honorary professorships at the Universities of Reading and King's College London. He has over 200 publications and 26 patents describing his work. His research interests lie mainly in drug delivery to the skin, nail and airways. To date, he has been involved in the pharmaceutical development of over 38 products that are now on the market in Europe, America and Japan. Prior to MedPharm he was an academic in the Pharmacy Department at KCL.

David Parker

Non-Executive Director

David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, Mr. Parker was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Avista Pharma, Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. Mr. Parker currently heads Ampersand’s European office, which is based in Amsterdam.

Trevor Wahlbrink

Non-Executive Director

Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the Boards of Directors of Avista Pharma, Confluent Medical and MedPharm. His prior Board Directorships have included Corpus Medical, Elite One Source Nutritional Services and ETE Medical. Mr. Wahlbrink is based in Ampersand’s Wellesley, MA USA offices.

Norman Barras

Board Member

Norman is an independent consultant with an extensive career in pharmaceutical research, contract manufacturing and development which included senior leadership roles at Patheon, Penn/PCI Pharmaceuticals and Lonza Biologics. He has over 30 years of experience in the pharmaceutical industry.

Patrick Walsh

Non-Executive Director

An experienced CEO & company Director whose leadership teams are recognized for their stellar performance and documented achievements. He has extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations. Patrick has served as Chairman, Non-Executive Chairman and a company Director and has been appointed to serve on audit, nominating and compensation committees. Patrick brings considerable experience in mergers and acquisitions as well as documented experience in turnaround and growth opportunities in the contract service, pharmaceutical or specialty pharma sectors. He has extensive experience in leading high-performing, private-equity backed organizations.

Paul Johnson MedPharm

Paul H. Johnson

Board Member

Paul joined MedPharm's Board of Directors in 2018 and is currently an Operating Partner at Ampersand. Paul was previously the CEO and President of Renaissance Topicals Division and DPT Laboratories, which were both sold to Mylan in 2016. During his time at DPT, Paul was instrumental in the start-up and growth of Healthpoint Biologics, which sold to Smith & Nephew in 2011, and Coria, which sold to Valeant in 2008. Paul also spent time at Johnson & Johnson where he led an initiative to enter and expand operations in China. Paul holds a B.A. from the University of Texas at El Paso and an M.B.A from Southern Methodist University.